- Home
- JAGX vs IMRN Comparison
JAGX vs IMRN Comparison
Compare JAGX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- IMRN
- Stock Information
- Founded
- JAGX 2013
- IMRN 1994
- Country
- JAGX United States
- IMRN Australia
- Employees
- JAGX N/A
- IMRN N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- IMRN Health Care
- Exchange
- JAGX Nasdaq
- IMRN Nasdaq
- Market Cap
- JAGX 12.9M
- IMRN 15.0M
- IPO Year
- JAGX N/A
- IMRN N/A
- Fundamental
- Price
- JAGX $0.86
- IMRN $1.90
- Analyst Decision
- JAGX
- IMRN Strong Buy
- Analyst Count
- JAGX 0
- IMRN 1
- Target Price
- JAGX N/A
- IMRN $5.00
- AVG Volume (30 Days)
- JAGX 311.0K
- IMRN 4.7K
- Earning Date
- JAGX 03-31-2025
- IMRN 03-03-2025
- Dividend Yield
- JAGX N/A
- IMRN N/A
- EPS Growth
- JAGX N/A
- IMRN N/A
- EPS
- JAGX N/A
- IMRN N/A
- Revenue
- JAGX $10,480,000.00
- IMRN $3,271,194.00
- Revenue This Year
- JAGX $18.18
- IMRN N/A
- Revenue Next Year
- JAGX $40.06
- IMRN N/A
- P/E Ratio
- JAGX N/A
- IMRN N/A
- Revenue Growth
- JAGX N/A
- IMRN 171.67
- 52 Week Low
- JAGX $0.78
- IMRN $1.65
- 52 Week High
- JAGX $21.60
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- JAGX 45.91
- IMRN 43.76
- Support Level
- JAGX $0.78
- IMRN $1.89
- Resistance Level
- JAGX $1.03
- IMRN $2.05
- Average True Range (ATR)
- JAGX 0.07
- IMRN 0.08
- MACD
- JAGX 0.01
- IMRN -0.02
- Stochastic Oscillator
- JAGX 30.44
- IMRN 3.85
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.